This public procurement record has 3 releases in its history.

TenderCancellation

09 Nov 2026 at 13:41

Tender

01 Oct 2026 at 12:04

Planning

20 May 2026 at 13:59

Summary of the contracting process

Healthcare Quality Improvement Partnership Ltd sought a supplier for the National Early Inflammatory Autoimmune Diseases Audit, a national clinical audit and healthcare quality improvement service. The work covers continuous prospective data collection and analysis, benchmarking healthcare providers against national clinical guidance and standards, and supporting services to improve care. The supplier is also to develop a minimum viable paediatric inflammatory arthritis pathway dataset and reporting framework, maintain an organisational survey, provide targeted improvement support and engage clinicians, patients, carers and the public. Expected outputs include interactive metric results, an annual report, validated patient-reported outcome measures, improvement resources and identification of outliers. The initial service covers NHS-funded care in England and Wales and publicly funded care in Jersey. The buyer is Healthcare Quality Improvement Partnership Ltd.

The buyer invited offers through an open procedure. The tender reached evaluation and clarification, but the procurement was terminated without award after further information about delivery scope, resourcing and commercial requirements led the authority to decide not to proceed under this process. The service requirements are to be reviewed before any decision on a future procurement. The stated core contract period was 1 October 2027 to 30 September 2030, with a possible extension of up to 24 months. The core budget was capped at £778,316 excluding VAT (£933,979.20 including VAT), with bids above that limit liable to rejection. The published overall ceiling, including potential extensions and aspirational measures, was £6,417,788 excluding VAT (£7,701,346 including VAT); these additional elements were not guaranteed. Enquiries closed at 12:00 on 19 October 2026 and bids at 12:00 on 2 November 2026. Quality and cost were evaluated, with quality weighted at 90% and cost at 5%; social value criteria were included in the quality assessment.

The requirement suits suppliers with experience delivering national clinical audits and translating health data into practical quality improvement. Strong bids needed to demonstrate robust data acquisition, information governance, data quality and analysis, and sound statistical and methodological input. The work also calls for programme leadership, governance, risk management and reliable delivery of timely reporting, alongside effective engagement with healthcare providers, clinicians, patients, carers, charities and public stakeholders. Suppliers should be able to benchmark performance, identify variation and outliers, and support improvement across services rather than only those performing poorly. Capability to develop clinical datasets and reporting for paediatric inflammatory arthritis, align audit measures with national guidance, and produce accessible interactive outputs is relevant. The buyer marked the opportunity as suitable for SMEs and voluntary, community and social enterprises. The terminated process offers no route to award; requirements may inform a future procurement after review.

How relevant is this notice?

Notice Information

Notice Title

National Early Inflammatory Autoimmune Diseases Audit

Notice Description

The contract is expected to initially be delivered for NHS-funded care in England and Wales, and publicly funded care in Jersey for a period of three years, at a maximum total budget of up to PS933,979.20 GBP including VAT and PS778,316.00 GBP excluding VAT. Bids exceeding this limit will be rejected. There is potential to extend the contract for up to two additional years as well as the option to include other Devolved Nations and/or Crown Dependencies, aspirational measures and discretionary inflationary uplifts (all of which will be defined in the service specification). The maximum budget 'core' value of PS933,979.20 GBP including VAT and PS778,316.00 GBP excluding VAT, excludes the potential two-year extension and aspirational intent as included in section 14.4 of Annex A - Service Specification The contract may be extended for up to 24 months at a pro rata value of the core three- year funding, estimated at up to PS518,877 excluding VAT. This proposed extension value may also include pro rata funding of any additional aspirational measures invoked in the first three years of the contract. For example: If an aspirational annual requirement costing PS500,000 per year is invoked in year three, then the extension funding (if the aspirational measure is continued) will be the above figures plus the additional PS500,000 per year. Further to this funding, the specification contains a list of aspirational measures which will be expected to be modified into the contract should the need and funding become available. The aspirational intent value, including the potential two- year extension and core 3 year value means an overall ceiling value for this contract of up to PS6,417,788 excluding VAT and PS7,701,346 including VAT. This aspirational intent has the potential to be invoked fully, partially, or not at all, and the Authority cannot guarantee that the successful supplier will be required to do any of the aspirational measures listed in section 14.4 of Annex A - Service Specification The role of a national clinical audit is to stimulate healthcare quality improvement through the provision of high-quality information on the organisation, delivery and outcomes of healthcare, together with tools and support to enable healthcare providers and other audiences to make best use of this information. Outcomes are benchmarked against available national guidance and standards e.g. quality standards from the National Institute for Health and Care Excellence (NICE), and those from other established professional and patient sources. Successful national audits are those where the individuals who are engaging with and using the audit results are also in a position to improve the system, and where there is a shared understanding of what good care looks like. National clinical audits are expected to: a.Develop a robust, high-quality audit designed around key quality metrics likely to best support local and national healthcare quality improvement. b.Detect, describe and help reduce unwarranted clinical variation by systematically benchmarking performance, identifying outliers, and supporting services to understand variation in outcomes, processes and experience. c.Achieve, articulate and maintain close alignment with relevant NICE national guidance and quality standards throughout the audit, as appropriate. d.Enable healthcare quality improvement through the provision of timely, high-quality data that compares providers of healthcare, and comprises an integrated mixture of named Trust or Health board, Integrated Care System (ICS), commissioner, multidisciplinary team (MDT), possibly consultant or clinical team level and other levels of reporting. e.Engage patients, carers and the public in a meaningful way, achieving a strong patient voice which informs and contributes to the design, functioning, outputs and direction of the audit. f.Consider the value and feasibility of linking data at an individual patient level to other relevant national datasets either from the outset or in the future and plan for these linkages from the inception of the contract. g.Ensure robust methodological and statistical input at all stages of the audit. h.Identify from the outset the full range of audiences for the reports and other audit outputs and plan and tailor them accordingly. i.Provide audit results in a timely, accessible and meaningful manner to support healthcare quality improvement, minimising the reporting delay and providing continual access to each unit for their own data. j.Utilise strong and effective project and programme management to deliver audit outputs on time and within budget. k.Develop and maintain strong engagement with local clinicians, networks, commissioners, patients and their families and carers and charity and community support groups to drive improvements in services. l.Deliver high-quality audit outputs, benchmarking and quality improvement as a priority. At the time of writing the specification, requirements include (but please also refer to the potential future aspirational intent section): 1. Audit Purpose The overall ambition of the audit is to continue to capture and report data on the performance of individual healthcare providers against the National Institute for Health and Care Excellence (NICE) Quality Standard QS33: Rheumatoid Arthritis in Adults, Quality standard QS214: Rare diseases, and other relevant national standards and guidance, (see Appendix 1). 2. Paediatric Inflammatory Arthritis Pathway The supplier should work with the wider Dataset and Methodology Stakeholder Group to develop, maintain and report against a minimum viable paediatric inflammatory arthritis pathway. The initial focus should be on establishing a clinically meaningful dataset and reporting framework sufficient to describe the patient pathway and support audit activity. Initial measures should focus on a limited number of priority areas agreed with funders and stakeholders, for example referral, diagnosis and treatment timelines. The updated GIRFT Paediatric Inflammatory Arthritis Pathway guidance, anticipated for publication in January 2027, should be considered a key reference for the future development of the dataset, measures and reporting framework. The supplier should work with the wider Dataset and Methodology Stakeholder Group to review and align the dataset, metrics and reporting outputs with the recommendations and standards set out within the GIRFT guidance, ensuring ongoing relevance and consistency with national best practice. Any expansion beyond the core pathway, including additional metrics, PROMs/PREMs, transition measures and broader pathway development, should be considered future aspirational intent subject to feasibility, resources and further funding. 3. Data Collection and Audit Design The supplier should continue to deliver a continuous prospective clinical audit and work with the Dataset and Methodology Group to ensure the audit dataset remains clinically relevant and proportionate. The supplier is expected to collaborate with specialist disease-specific clinical groups to support interpretation of findings and improve case ascertainment and recruitment rates. 4. Organisational Survey and Quality Improvement The supplier should review and maintain the organisational survey to ensure it remains proportionate and aligned with audit objectives. Priority should be given to maximising analysis and utilisation of existing data rather than increasing data collection burden in collaboration with the wider Dataset and Methodology Stakeholder Group. The organisational survey should support the audit's quality improvement objectives by enabling a deeper understanding of service delivery, workforce capacity, variation in practice and barriers to high-quality care. 5. Benchmarking and Improvement The audit is expected to support continuous improvement across all services. While identifying high-performing and outlier services remains important, the audit should also support improvement among services performing at or around the national average, where the greatest overall gains may be achieved. Benchmarking should encourage year-on-year improvement within individual services and provide meaningful insights that motivate all providers to improve, regardless of their current position relative to national performance. 6. Targeted improvement support The supplier should provide targeted quality improvement support following each annual audit cycle. Activities should build on existing professional networks, collaboratives and stakeholder infrastructure wherever possible rather than creating wholly new arrangements. Improvement support should be designed to benefit healthcare providers across the performance spectrum, including those performing at a middle level where the greatest overall gains may be achieved, while also supporting services experiencing significant challenges or demonstrating exceptional practice. Learning generated through quality improvement activities should be shared with all participating healthcare providers to maximise the impact of the audit programme. The anticipated outputs are: 1.Near real-time dynamic and interactive metric results. 2.Publication of an annual state of the nation report with the inclusion of an organisational survey. 3.Incorporation of validated Patient Reported Outcome Measures. 4.Quality improvement resources. 5.The identification and notification of outliers. For further information on the current audit, currently delivered by the British Society for Rheumatology (BSR) please head to: https://www.rheumatology.org.uk/improving-care/audits/neiaa

Lot Information

Lot 1

Renewal: Up to 24 month extension at a value of up to PS518,877 excluding VAT. This value also excludes any aspirational intent measures that may be invoked in advance of contract extension but intended to continue during the extension period. Therefore, this extension value is subject to significantly change based on any aspirational measures invoked.

Planning Information

Healthcare Quality Improvement Partnership (HQIP) is seeking to engage with the market on the recommissioning of the National Early Inflammatory Autoimmune Diseases Audit. The Authority is looking to build on the successes of the existing audit currently contracted with the British Society for Rheumatology (BSR). Further information as well as details of the current audit can be found at: https://www.rheumatology.org.uk/improving-care/audits/neiaa HQIP will be looking to hold a pre-market engagement session with potential suppliers on Friday 3rd July 2026 12.00pm – 14.00pm. Also in attendance will be system partners and service specialists including charities. The aim of the pre market engagement session is for interested parties to hear and contribute to discussions with system experts and patient groups that will feed in to HQIP’s final decisions on the scope of the audit during this next contract period, and the anticipated outcomes over the 3-5 years of the audit. The existing specification is available for review by any interested parties and whilst it will provide information on how the current audit was scoped, it is important to understand that the recommissioning of this audit may amend the requirements. At this point, the Authority is planning to run this procurement under an open tender. The proposed dates (subject to change solely at the Authorities discretion) are as follows: •3rd July 2026 - Pre Market Engagement Session •Publication of tender opportunity – October 2026 •Evaluation of submitted bids – November – December 2026 •Award – March 2027 •Contract start - 1st October 2027 Whilst the Authority intends to stick to the timeline, it may deviate away from it at any time. The expected value of the contract will be subject to increase under aspirational intent measures which will be defined in the service specification at point of tender. The aspirational intent will cover the value range and mechanisms for invoking each element of it. If you would like to join this premarket engagement event, please register your interest at - https://forms.office.com/e/8wn8xiRwxt You may also use this opportunity to request a copy of the existing project specification.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-069d7c
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/106242-2026
Current Stage
Tender
All Stages
Planning, Tender

Procurement Classification

Notice Type
UK12 - Procurement Termination Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
SME, VCSE
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services


CPV Codes

85100000 - Health services

Notice Value(s)

Tender Value
£6,417,788 £1M-£10M
Lots Value
£6,417,788 £1M-£10M
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
9 Nov 20261 weeks ago
Submission Deadline
2 Nov 2026Expired
Future Notice Date
1 Oct 2026Expired
Award Date
Not specified
Contract Period
1 Oct 2027 - 30 Sep 2030 3-4 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Cancelled
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
HEALTHCARE QUALITY IMPROVEMENT PARTNERSHIP
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
EC2V 6DL
Postcode Area
Central London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI3 Inner London - West
Small Region (ITL 3)
TLI35 Westminster and City of London
Delivery Location
Not specified

Local Authority
City of London
Electoral Ward
Cheap
Westminster Constituency
Cities of London and Westminster

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...